RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis

References

• Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am.27(2), 269–281 (2001).
   PubMed Web of Science ®Google Scholar
• Rupp I, Boshuizen HC, Dinant HJ, Jacobi CE, van den Bos GA. Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand. J. Rheumatol.35(3), 175–181 (2006).
   PubMed Web of Science ®Google Scholar
• Machold KP, Stamm TA, Eberl GJ et al. Very recent onset arthritis – clinical, laboratory, and radiological findings during the first year of disease. J. Rheumatol.29(11), 2278–2287 (2002).
   PubMedGoogle Scholar
• Ollier WE, Harrison B, Symmons D. What is the natural history of rheumatoid arthritis? Best Pract. Res. Clin. Rheumatol.15(1), 27–48 (2001).
   PubMed Web of Science ®Google Scholar
• van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br. J. Rheumatol.34(Suppl.), 274–278 (1995).
   PubMedGoogle Scholar
• Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann. Rheum. Dis.63(3), 221–225 (2004).
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum.54(9), 2784–2792 (2006).
   PubMed Web of Science ®Google Scholar
• Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum.43(1), 14–21 (2000).
   PubMed Web of Science ®Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum.48(10), 2750–2762 (2003).
   PubMed Web of Science ®Google Scholar
• Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine71(6), 518–524 (2004).
   PubMed Web of Science ®Google Scholar
• Albers JM, Kuper HH, van Riel PL et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford)38(5), 423–430 (1999).
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann. Rheum. Dis.61(4), 335–340 (2002).
   PubMed Web of Science ®Google Scholar
• Reisine S, McQuillan J, Fifield J. Predictors of work disability in rheumatoid arthritis patients. A five-year followup. Arthritis Rheum.38(11), 1630–1637 (1995).
   PubMedGoogle Scholar
• Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum.50(1), 36–42 (2004).
   PubMed Web of Science ®Google Scholar
• Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum.58(9), 2622–2631 (2008).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis.69(4), 631–637 (2010).
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewé R, Breedveld F et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. Ann. Rheum. Dis.69(6), 964–975 (2010).
   PubMed Web of Science ®Google Scholar
• Landewe RB, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum.46(2), 347–356 (2002).
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum.52(11), 3381–3390 (2005).
   PubMed Web of Science ®Google Scholar
• Puolakka K, Kautiainen H, Mottonen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum.52(1), 36–41 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Nilsson JA et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis.66(5), 670–675 (2007).
   PubMed Web of Science ®Google Scholar
• van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. Arthritis Rheum.61(1), 4–12 (2009).
   PubMed Web of Science ®Google Scholar
• Radner H, Smolen J, Aletaha D. Remission of rheumatoid arthritis: benefits from socioeconomic and quality of life perspectives. Presented at: American College of Rheumatology 2009. Philadelphia, PA, USA, 17–21 October 2009 (Abstract 1382).
   Google Scholar
• van der Heide A, Jacobs JW, Bijlsma JW et al. The effectiveness of early treatment with ‘second-line’ antirheumatic drugs. A randomized, controlled trial. Ann. Intern. Med.124(8), 699–707 (1996).
   PubMed Web of Science ®Google Scholar
• Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med.111(6), 446–451 (2001).
   PubMed Web of Science ®Google Scholar
• Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the ‘anchor drug’ for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol.21(5 Suppl. 31), S179–S185 (2003).
   PubMed Web of Science ®Google Scholar
• Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med.159(21), 2542–2550 (1999).
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet363(9410), 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54(1), 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum.41(9), 1552–1563 (1998).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med.350(25), 2572–2581 (2004).
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum.54(9), 2817–2829 (2006).
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford)48(9), 1114–1121 (2009).
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet354(9194), 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Finckh A, Ciurea A, Brulhart L et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum.56(5), 1417–1423 (2007).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med.353(11), 1114–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis.67(11), 1516–1523 (2008).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann. Rheum. Dis.62(12), 1195–1198 (2003).
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum.56(1), 13–20 (2007).
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm. Bowel Dis.13(11), 1323–1332 (2007).
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs22(5), 315–329 (2008).
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Brown D, Henry A, Palframan R, Stephens S. Effect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritis. Ann. Rheum. Dis.66(Suppl. II), 296 (2007).
   Web of Science ®Google Scholar
• Weaver AL. Differentiating the new rheumatoid arthritis biologic therapies. J. Clin. Rheumatol.9(2), 99–114 (2003).
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol.17(8), 780–783 (1999).
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum.58(11), 3319–3329 (2008).
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis.68(6), 797–804 (2009).
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum.38(6), 727–735 (1995).
   PubMed Web of Science ®Google Scholar
• Strand V, Mease P, Burmester GR et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res. Ther.11(6), R170 (2009).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Smolen JS, Emery P et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum.61(11), 1592–1600 (2009).
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis.68(6), 805–811 (2009).
   PubMed Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Smolen J et al. The efficacy of certolizumab pegol added to methotrexate is sustained over 2 years in the treatment of rheumatoid arthritis. Arthritis Rheum.60(Suppl.), S622 (2009).
   Google Scholar
• Strand V, Fleischmann R, Kvien TK et al. Certolizumab pegol added to methotrexate provides lasting improvements in patient-reported outcomes over 2 years. Presented at: American College of Rheumatology/Association of Rheumatology Health Professionals 2009 Meeting. Philadelphia, PA, USA, 17–21 October 2009.
   Google Scholar
• van vollenhoven R, Smolen J, Schiff M et al. Safety update on certolizumab pegol in patients with active rheumatoid arthritis. Arthritis Rheum.60(Suppl.), S636 (2009).
   PubMedGoogle Scholar
• Stephens P, Nesbitt A, Foulkes R. Placental transfer of the anti-TNF antibody TN3 in rats: comparison of immunoglobulin G1 and pegylated Fab versions. Gut55(Suppl.), A8 (2006).
   PubMedGoogle Scholar